Pharmacological modulation of microparticle release: New strategies for the management of atherothrombotic vascular disorders

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 840-849

  Montoro García, Silvia ^a,b   Orenes Piñero, Esteban ^a   Marín, Francisco ^a   Valdés, Mariano ^a   Lip, Gregory Y H ^b   Shantsila, Eduard ^b  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Inflammation; Microparticles; Mode of action; Pharmacological drugs; Platelet activation; Thrombosis

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 CHLORO 5 NITROBENZANILIDE; ABCIXIMAB; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BEVACIZUMAB; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ETORICOXIB; FENOFIBRATE; FLUINDOSTATIN; FONDAPARINUX; LOSARTAN; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SIMVASTATIN; STATIN; THROMBIN INHIBITOR; UNINDEXED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; MONOCYTE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; VASCULAR DISEASE; VEIN THROMBOSIS;

CELL-DERIVED MICROPARTICLES; FIBRINOLYTIC AGENTS; HUMANS; PLATELET ACTIVATION; THROMBOSIS; VASCULAR DISEASES;

EID: 84856440621     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277789     Document Type: Review

References (129)

1. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
2. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol 2002; 7: 40-53.
3. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008; 123: 8-23.
4. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010; 125 Suppl 1: S46-S48.
5. Trappenburg MC, van Schilfgaarde M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94: 911-918.
6. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001; 112: 81-90.
7. Sinning JM, Losch J, Walenta K, Bohm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2010.
8. Nozaki T, Sugiyama S, Sugamura K, et al. Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail 2010; 12: 1223-1228.
9. Jung KH, Chu K, Lee ST, et al. Circulating endothelial microparticles as a marker of cerebrovascular disease. Ann Neurol 2009; 66: 191-199.
10. Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010; 2010: 250476.
11. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
12. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-180.
13. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
14. Hayasaka K, Moriyama T, Chiba H, Matsuno K. [Advancement of platelet activation measurement: focusing on platelet-derived microparticle measurement]. Rinsho Byori 2006; 54: 250-255.
15. Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transplant 2009; 28: 1081-1086.
16. Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-2652.
17. Mause SF, Ritzel E, Liehn EA, et al. Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation 2010; 122: 495-506.
18. Mostefai HA, Agouni A, Carusio N, et al. Phosphatidylinositol 3- kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J Immunol 2008; 180: 5028-5035.
19. Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358-2368.
20. Pisetsky DS. Platelet microparticles: making blood a bad humor. J Rheumatol 2011; 38: 590-592.
21. Sapet C, Simoncini S, Loriod B, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 2006; 108: 1868-1876.
22. Montoro-Garcia S, Shantsila E, Marin F, Blann A, Lip GY. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 2011.
23. Anderson HC, Mulhall D, Garimella R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest 2010; 90: 1549-1557.
24. Lubsczyk B, Kollars M, Hron G, Kyrle PA, Weltermann A, Gartner V. Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur J Clin Invest 2010; 40: 477-482.
25. Shirafuji T, Hamaguchi H, Kanda F. Measurement of plateletderived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay. Kobe J Med Sci 2008; 54: E55-E61.
26. Bulut D, Becker V, Mugge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol 2011; 89: 239-244.
27. Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 2007; 131: 809-815.
28. Serebruany VL, Malinin AI, Pokov AN, Hanley DF. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Clin Ther 2008; 30: 249-259.
29. Shouzu A, Nomura S, Omoto S, Hayakawa T, Nishikawa M, Iwasaka T. Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 167-173.
30. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
31. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-1126.
32. Goto S, Tamura N, Li M, et al. Different effects of various anti- GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-2030.
33. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
34. Ben-Hadj-Khalifa-Kechiche S, Hezard N, Poitevin S, et al. Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles. J Thromb Thrombolysis 2010; 30: 412-418.
35. Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2006; 2: 365-370.
36. Christersson C, Johnell M, Siegbahn A. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. Thromb Res 2010; 126: e327-e333.
37. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007; 100: 1047-1051.
38. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
39. Mobarrez F, He S, Broijersen A, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106.
40. Tehrani S, Mobarrez F, Antovic A, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010; 126: e225-31.
41. Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H.Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005; 3: 1168-1171.
42. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann Med 2010; 42: 394-403.
43. Bruni F, Puccetti L, Pasqui AL, et al. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med 2003; 3: 45-53.
44. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-41.
45. Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rhokinase pathway. Biochem Biophys Res Commun 2004; 320: 34-38.
46. Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets anderythrocytes in subjects with metabolic syndrome: Relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2010.
47. Diamant M, Tushuizen ME, Abid-Hussein MN, et al. Simvastatininduced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008; 100: 489-97.
48. Diehl P, Aleker M, Helbing T, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis 2011; 31: 173-179.
49. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211-217.
50. Boulanger CM, Amabile N, Guerin AP, et al. In vivo shear stress determines circulating levels of endothelial microparticles in endstage renal disease. Hypertension 2007; 49: 902-908.
51. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-3545.
52. Nomura S, Inami N, Shouzu A, Urase F, Maeda Y. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009; 20: 406-414.
53. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105: 30A-35A.
54. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial Microparticle Formation by Angiotensin II Is Mediated via AT1R/NADPH Oxidase/Rho Kinase Pathways Targeted to Lipid Rafts. Arterioscler Thromb Vasc Biol 2011.
55. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of plateletmonocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes. Clin Cardiol 2007; 30: 26-31.
56. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
57. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172-177.
58. Labios M, Martinez M, Gabriel F, Guiral V, Ruiz-Aja S, Aznar J. Cytoplasmic free calcium mobilization in platelets, expression of P-selectin, phosphatidylserine, and microparticle formation, measured by whole blood flow cytometry, in hypertensive patients. Effect of doxazosin GITS. Thromb Res 2006; 117: 403-9.
59. Tamburrelli C, Crescente M, Izzi B, et al. Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thromb Res 2011.
60. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003; 98: 1578-1586.
61. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22: 61-69.
62. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol 2011; 90: 447-453.
63. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res 2010; 125: 511-512.
64. Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105: 14-20.
65. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
66. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 5: 2445-2452.
67. Fu Y, Zhou J, Li H, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost 2010; 104: 1235-1241.
68. Williams JB, Jauch EC, Lindsell CJ, Campos B. Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis. Acad Emerg Med 2007; 14: 685-690.
69. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49: 2073-2080.
70. Benameur T, Tual-Chalot S, Andriantsitohaina R, Martinez MC. PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis. PLoS One 2010; 5: e12392.
71. Collier ME, Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1- integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol 2010; 30: 1810-1817.
72. Chahed S, Leroyer AS, Benzerroug M, et al. Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferation. Diabetes 2010; 59: 694-701.
73. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 166-174.
74. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009; 16: 94-112.
75. Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, Seica RM. Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol 2011; 163: 424-437.
76. Yu J, Zhang Z, Li Z, et al. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 2010; 38: 86-94.
77. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferatoractivated receptor-gamma-mediated effects in the vasculature. Circ Res 2008; 102: 283-294.
78. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480.
79. Tesse A, Al-Massarani G, Wangensteen R, Reitenbach S, Martinez MC, Andriantsitohaina R. Rosiglitazone, a peroxisome proliferatoractivated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. J Pharmacol Exp Ther 2008; 324: 539-547.
80. Esposito K, Ciotola M, Giugliano D. Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1926.
81. Rinaldi B, Pieri L, Donniacuo M, et al. Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats. Shock 2009; 32: 638-644.
82. Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 2008; 11: 361-367.
83. Shimazu T, Inami N, Satoh D, et al. Effect of acarbose on plateletderived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis 2009; 28: 429-435.
84. Baron M, Leroyer AS, Majd Z, et al. PPARalpha activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis 2011.
85. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
86. Levonen AL, Vahakangas E, Koponen JK, Yla-Herttuala S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation 2008; 117: 2142-2150.
87. Marin C, Ramirez R, Delgado-Lista J, et al. Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium. Am J Clin Nutr 2011; 93: 267-274.
88. Ellis GR, Anderson RA, Chirkov YY, et al. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol 2001; 37: 564-570.
89. Morel O, Jesel L, Hugel B, et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003; 1: 171-177.
90. Zwicker JI, Trenor CC, 3rd, Furie BC, Furie B. Tissue factorbearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31: 728-733.
91. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-2127.
92. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 2004; 43: 428-433.
93. Stockton RA, Jacobson BS. Modulation of cell-substrate adhesion by arachidonic acid: lipoxygenase regulates cell spreading and ERK1/2-inducible cyclooxygenase regulates cell migration in NIH- 3T3 fibroblasts. Mol Biol Cell 2001; 12: 1937-1956.
94. Barry OP, Kazanietz MG, Pratico D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2- dependent prostaglandin formation via a protein kinase C/mitogenactivated protein kinase-dependent pathway. J Biol Chem 1999; 274: 7545-7556.
95. Friedrich EB, Tager AM, Liu E, et al. Mechanisms of leukotriene B4--triggered monocyte adhesion. Arterioscler Thromb Vasc Biol 2003; 23: 1761-1767.
96. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood 2007; 110: 2432-2439.
97. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30-38.
98. Ou ZJ, Chang FJ, Luo D, et al. Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. Am J Physiol Endocrinol Metab 2011; 300: E661-E668.
99. Distler JH, Akhmetshina A, Dees C, et al. Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum 2011.
100. Mezentsev A, Merks RM, O'Riordan E, et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289: H1106-H11014.
101. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem 2003; 278: 18008-18014.
102. Leroyer AS, Rautou PE, Silvestre JS, et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008; 52: 1302-1311.
103. Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol 2007; 178: 641-646.
104. Pakala R. Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc Radiat Med 2004; 5: 20-26.
105. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2- dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004; 101: 591-596.
106. Huber LC, Jungel A, Distler JH, et al. The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis 2007; 12: 363-374.
107. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endotheliumderived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004; 286: H1910-H1915.
108. Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab 2006; 91: 3676-3679.
109. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135.
110. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-144.
111. Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011; 108: 335-43.
112. Nolan S, Dixon R, Norman K, Hellewell P, Ridger V. Nitric oxide regulates neutrophil migration through microparticle formation. Am J Pathol 2008; 172: 265-273.
113. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008; 173: 1210-1219.
114. Tesse A, Martinez MC, Hugel B, et al. Upregulation of proinflammatory proteins through NF-kappaB pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol 2005; 25: 2522-2527.
115. Mastronardi ML, Mostefai HA, Meziani F, Martinez MC, Asfar P, Andriantsitohaina R. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011; 39: 1739-1748.
116. Mortaza S, Martinez MC, Baron-Menguy C, et al. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. Crit Care Med 2009; 37: 2045-2050.
117. Angelot F, Seilles E, Biichle S, et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. Haematologica 2009; 94: 1502-1512.
118. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissuefactor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
119. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-178.
120. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005; 78: 1318-1326.
121. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat- George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99: 3962-3970.
122. Biro E, Sturk-Maquelin KN, Vogel GM, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-2568.
123. Pluskota E, Woody NM, Szpak D, et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood 2008; 112: 2327-2335.
124. Essayagh S, Xuereb JM, Terrisse AD, Tellier-Cirioni L, Pipy B, Sie P. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost 2007; 98: 831-837.
125. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004; 124: 376-384.
126. Densmore JC, Signorino PR, Ou J, et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006; 26: 464-471.
127. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004; 109: 1653-1659.
128. Distler JH, Jungel A, Huber LC, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005; 102: 2892-2897.
129. Cerri C, Chimenti D, Conti I, Neri T, Paggiaro P, Celi A. Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator synthesis by human airway epithelial cells. J Immunol 2006; 177: 1975-1980.